Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Opdivo (nivolumab)
pCPA File Number:
21111
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CADTH Project Number:
pCODR 10147
pCPA Engagement Letter Issued:
2019-06-26
Negotiation Process Concluded:
2019-09-06